Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index; 20 of the 98 sources its claims cite were checked for support.

Long-term neurological consequences following benzodiazepine exposure: A scoping review

Open access

Abstract

Benzodiazepine acute withdrawal syndrome is well known, but the long-term neurological consequences of benzodiazepine exposure are much less familiar. A scoping review was conducted of electronic databases for studies that reported on patient outcomes four or more weeks after complete cessation of benzodiazepine use. Forty-six results were retrieved in total, some of which provided signals for protracted symptoms, often reported as incidental findings, and others that showed benzodiazepine discontinuation was beneficial. Some overlap occurred in the outcomes, but these two groups of studies suggest that the benefits of benzodiazepine discontinuation for many patients tended to obscure the more prolonged, severe, and sometimes debilitating symptoms that persisted for months and years in a subpopulation of patients. The prevalence or trajectory of these enduring symptoms could not be determined from these studies. Further elucidation of the potential neurotoxicity of benzodiazepines is needed to better understand protracted symptoms and their treatment. Clinicians, patients, and the healthcare system must be cognizant of the risks of benzodiazepine exposure beyond two to four weeks.

Overview

CoChat Summary

TL;DR

This scoping review of 46 studies found signals that a subpopulation of patients experiences protracted neurological symptoms persisting four or more weeks after benzodiazepine cessation, while many studies showed discontinuation was beneficial. The prevalence and trajectory of enduring symptoms could not be determined, and the authors call for further research into possible benzodiazepine neurotoxicity.

Key findings

  • The search retrieved 14,097 publications and included 46 studies; the Results section reports that 28 of 46 (61%) provided signals of a protracted withdrawal phase, while the Discussion states 27 provided such signals.
  • Acute withdrawal occurred in up to 100% of participants in some included studies, whereas prolonged symptoms were reported in approximately 30% of benzodiazepine patients; no incidence or prevalence data were found.
  • Fourteen studies (30.4%) had as their main finding that benzodiazepine discontinuation was unproblematic and beneficial, but severe protracted symptoms were also reported, including one study where 100% of 20 benzodiazepine patients had neurologic symptoms at six months after complete cessation and another where 28% required antidepressant therapy at 12 weeks after discontinuation.
  • No clear risk or protective factors for protracted symptoms were identified, and no randomized clinical trials were designed with enduring symptoms after complete benzodiazepine cessation as an endpoint.

Methods

  • Scoping review following JBI evidence synthesis methodology and PRISMA-ScR guidelines; searches were run in August 2023 and updated in December 2024 across Ovid MEDLINE(R) ALL (1946 to December 6, 2024), Embase, and APA PsycInfo.
  • Inclusion criteria were adults ≥18 years who used benzodiazepines for >2 weeks and discontinued for >4 weeks, excluding primary psychotic illness or bipolar disorder; experimental studies, observational studies, case studies/series, and clinical trials were included, while clinical trial registrations, commentaries, editorials, correspondence, reviews, conference abstracts, animal studies, grey literature, and non-English/non-peer-reviewed articles were excluded.
  • A descriptive analysis of extracted data was performed to identify article type and summarize relevant data for signals of benzodiazepine-induced neurological dysfunction (BIND).

Limitations

  • The paper states that no randomized clinical trials were specifically designed to look for enduring symptoms following complete benzodiazepine cessation, so protracted symptoms observed were signals or incidental findings rather than primary endpoints; prevalence and trajectory could not be determined.
  • The paper states that the scoping review allowed a broad range of studies of variable quality, that terminology in the literature was inconsistent, and that grey literature and clinical trial registrations were excluded.
  • Evident from the text: the Results and Discussion report different counts of studies providing signals (28 vs. 27), and the included literature was mostly published before 1996 with comparatively few results after 2006.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0330277

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 PRISMA flow diagram adapted from Covidence review software. [27] At the end of the screening, 46 articles were considered.
Fig 1 PRISMA flow diagram adapted from Covidence review software. [27] At the end of the screening, 46 articles were considered.CC BY · PubMed Central
Fig 2 Bibliometric data on study results, showing most results from the scoping review are 20 or more years old. There is a considerable dearth of results in the period from 2006 to present.
Fig 2 Bibliometric data on study results, showing most results from the scoping review are 20 or more years old. There is a considerable dearth of results in the period from 2006 to present.CC BY · PubMed Central
Fig 3 The types and study designs of retrieved results, grouped by those that provided signals of benzodiazepine-induced neurological dysfunction (BIND), those that offered evidence that benzodiazepine discontinuation conferred benefits on patients, and those with no such relevant findings.
Fig 3 The types and study designs of retrieved results, grouped by those that provided signals of benzodiazepine-induced neurological dysfunction (BIND), those that offered evidence that benzodiazepine discontinuation conferred benefits on patients, and those with no such relevant findings.CC BY · PubMed Central

Verification

Claims the paper makes

16 Valid · 2 Not valid · 40 Not checked · 52 Own results and interpretations

54 more claims · 4 with their cited sources checked

Create a free account to see all 110 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 88 references

Research works printed but not linked: 5

  1. D Foster, 2018, Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal, 309
  2. Shade K, Ritvo A, Silvernail B, Martin P, Foster D, Huff C, et al. Benzodiazepine induced neurological dysfunction: an overview of adverse long-term neurological consequences following chronic use of benzodiazepines: a scoping review protocol. 2023. · DOI · Paper page
  3. P Peperkamp, 1993, The discontinuation of lorazepam and diazepam following sub-chronic therapy in anxious outpatients, J Drug Dev, 6, 171
  4. P Martin, 2017, Pharmacology of drugs of abuse., 308
  5. HC Rosenberg, 1985, Time course for development of benzodiazepine tolerance and physical dependence, Neurosci Biobehav Rev, 9, 123, 10.1016/0149-7634(85)90038-7 · DOI · Paper page

Cited by

See all 7

Metadata

Authors
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R.
Affiliations
  • University of Colorado Anschutz (US)
  • Vanderbilt University Medical Center (US)
  • Yale University (US)
Corresponding author
  • Shade, Kyla N.
  • Ritvo, Alexis D.
  • Silvernail, Bernard
  • Finlayson, A. J. Reid
  • Bressi, Jolene E.
  • Foster, D. E.
  • Martin, Ian J.
  • Piper, Christi
  • Martin, Peter R.
Venue
PLOS One
Published
2025-08-28
Volume
20
Issue
8
Pages
e0330277
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4413786647
Cited by
7
References
88
Citations by year
2026: 6 · 2025: 1
FWCI
0.86
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
benzodiazepines, benzodiazepine withdrawal, benzodiazepine discontinuation, neurotoxicity, benzodiazepine dependence
MeSH terms
Benzodiazepines, Humans, Nervous System Diseases, Substance Withdrawal Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term neurological consequences following benzodiazepine exposure: A scoping review. https://app.cochat.ai/papers/10.1371/journal.pone.0330277
The paper
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025). Long-term neurological consequences following benzodiazepine exposure: A scoping review. PLOS One. https://doi.org/10.1371/journal.pone.0330277

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.